These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 25851829

  • 21. Second primaries after major salivary gland cancer.
    Megwalu UC, Shin EJ.
    Otolaryngol Head Neck Surg; 2011 Aug; 145(2):254-8. PubMed ID: 21493280
    [Abstract] [Full Text] [Related]

  • 22. Radioactive Iodine Therapy in Differentiated Thyroid Cancer: An Update on Dose Recommendations and Risk of Secondary Primary Malignancies.
    Nguyen NC, Anigati EM, Desai NB, Öz OK.
    Semin Nucl Med; 2024 Jul; 54(4):488-496. PubMed ID: 38772827
    [Abstract] [Full Text] [Related]

  • 23. Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.
    Lang BH, Lo CY, Wong IO, Cowling BJ.
    Surgery; 2010 Dec; 148(6):1191-6; discussion 1196-7. PubMed ID: 21134551
    [Abstract] [Full Text] [Related]

  • 24. Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel.
    Izkhakov E, Barchana M, Liphshitz I, Silverman BG, Stern N, Keinan-Boker L.
    Thyroid; 2017 Jun; 27(6):793-801. PubMed ID: 28338430
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
    Zhang H, Cai Y, Zheng L, Zhang Z, Jiang N.
    Hell J Nucl Med; 2017 Jun; 20(1):3-10. PubMed ID: 28315902
    [Abstract] [Full Text] [Related]

  • 28. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
    Reinecke MJ, Ahlers G, Burchert A, Eilsberger F, Flux GD, Marlowe RJ, Mueller HH, Reiners C, Rohde F, van Santen HM, Luster M.
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.
    Giri S, Bhatt VR, Verma V, Pathak R, Bociek RG, Vose JM, Armitage JO.
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):569-574. PubMed ID: 28709798
    [Abstract] [Full Text] [Related]

  • 32. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
    Klubo-Gwiezdzinska J, Van Nostrand D, Burman KD, Vasko V, Chia S, Deng T, Kulkarni K, Wartofsky L.
    Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
    Chow SM, Yau S, Lee SH, Leung WM, Law SC.
    Int J Radiat Oncol Biol Phys; 2004 Jul 15; 59(4):992-1000. PubMed ID: 15234032
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
    Hisada M, Chen BE, Jaffe ES, Travis LB.
    J Natl Cancer Inst; 2007 Feb 07; 99(3):215-22. PubMed ID: 17284716
    [Abstract] [Full Text] [Related]

  • 37. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer.
    Jain KS, Sikora AG, Baxi SS, Morris LG.
    Cancer; 2013 May 15; 119(10):1832-7. PubMed ID: 23423883
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
    Gandhi S, Abhyankar A, Basu S.
    Nucl Med Commun; 2014 Feb 15; 35(2):205-9. PubMed ID: 24217429
    [Abstract] [Full Text] [Related]

  • 40. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
    Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD.
    Thyroid; 2010 Nov 15; 20(11):1235-45. PubMed ID: 21062195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.